Naturally occurring cutaneous anthrax: antibiotic treatment and outcome

Chemotherapy
Uner KayabasMehmet Doganay

Abstract

Cutaneous anthrax (CA) is the most common clinical presentation in human anthrax, but the duration of antibiotic therapy in naturally occurring CA is controversial. The aim of this study was to compare the clinical outcomes of patients receiving antibiotic treatment for either 3-5 days (group 1) or 7-10 days (group 2) in uncomplicated CA. A total of 66 patients were enrolled; 29 (44%) in group 1 and 37 (56%) in group 2. Infections were classified as mild (n = 22, 33%) or severe (n = 44, 67%) CA. There were no significant differences between the groups in symptom resolution time, fever clearance time, healing of lesions, development and healing of eschars, requirement for surgical intervention or the development of complications. Both edema resolution time and duration of hospital stay were longer in group 2. There were no therapeutic failures, relapses or deaths in either group. Steroid therapy was used in 32% of patients with severe CA, but a beneficial effect on resolution of edema was not demonstrated. These results suggest that short-course antibiotic therapy is as effective as standard-duration therapy in uncomplicated CA and that steroid therapy may not be effective.

References

Jan 1, 1991·Scandinavian Journal of Infectious Diseases·M Doğanay, N Aydin
Jun 1, 1968·Diseases of the Chest·J Y DoustK Kavoossi
Sep 9, 1999·The New England Journal of Medicine·T C DixonP C Hanna
Nov 13, 2001·The New England Journal of Medicine·M N Swartz
May 1, 2002·JAMA : the Journal of the American Medical Association·Thomas V InglesbyUNKNOWN Working Group on Civilian Biodefense
Jun 19, 2002·Antimicrobial Agents and Chemotherapy·Jean-Didier CavalloEric Hernandez
Jun 20, 2002·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A KayaB Ozkan
Aug 6, 2002·Scandinavian Journal of Infectious Diseases·O OncülA Pahsa
Aug 29, 2002·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A Bryskier
Sep 20, 2002·Scandinavian Journal of Infectious Diseases·Mustafa Z BakiciMustafa Turan
Nov 15, 2002·International Journal of Antimicrobial Agents·Itzhak Brook
Nov 19, 2002·Antimicrobial Agents and Chemotherapy·Pamala R CokerMartin E Hugh-Jones
Jul 5, 2003·International Journal of Antimicrobial Agents·Duygu EselBulent Sumerkan
Sep 1, 1955·A.M.A. Archives of Internal Medicine·H GOLD
May 15, 2008·Clinical and Experimental Dermatology·M K KarahocagilO Evirgen
Oct 24, 2008·Vector Borne and Zoonotic Diseases·Mehmet Doganay, Gokhan Metan
Nov 7, 2008·International Journal of Dermatology·Hamdi OzcanSelma Ay
Jan 28, 2010·Journal of Medicinal Chemistry·Dimitrios G Bouzianas
Sep 28, 2010·Journal of Infection and Public Health·Mehmet DoganayEmine Alp
Aug 3, 1946·Journal of the American Medical Association·H V ELLINGSONC HOWE
Nov 19, 2010·Pediatric Dermatology·Sinan AkbayramAhmet Faik Oner

❮ Previous
Next ❯

Citations

Mar 20, 2014·Cutaneous and Ocular Toxicology·Oktay EsmerAyse Serap Karadag
Jan 1, 2016·Vector Borne and Zoonotic Diseases·Emine Parlak, Mehmet Parlak
Mar 13, 2015·International Ophthalmology·Grant GillilandConnor Gilliland
Mar 5, 2015·The New England Journal of Medicine·Amesh A AdaljaThomas V Inglesby

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Cellulitis

Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. Discover the latest research on cellulitis here.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.